STZ treatment significantly increased eNOS and dihydrofolate reductase expression and SGLT2i therapy decreased it dose-dependently suggesting that SGLT2i therapy normalized these adverse effects of hyperglycemia, thereby preventing the compensatory up-regulation of these enzymes (Figure 4 A and C). This evidence concerns the gene DHFR and Hyperglycemia.